Kansas City Business Journal Names Cingulate’s Louis G. Van Horn a 2022 Chief Financial Officer of the Year
July 25 2022 - 1:45PM
Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical
company utilizing its proprietary Precision Timed Release™ (PTR™)
drug delivery platform technology to build and advance a pipeline
of next-generation pharmaceutical products, today announced that
Chief Financial Officer (CFO), Lou Van Horn, has been named a 2022
CFO of the Year by the Kansas City Business Journal. The milestone
marks the second time that Lou has received the honor.
Lou was among 16 CFOs representing the best in
financial management and have proven themselves invaluable to their
companies and organizations. A panel of independent judges selected
this year’s honorees who were celebrated at a special ceremony July
22 at the Loews Kansas City Hotel.
“Lou’s character, expertise, and principle
driven leadership make him one of the best CFOs in our industry,”
said Shane J. Schaffer, Cingulate Chairman and CEO. “His
dedication, loyalty, and values make me proud to call him a good
friend.”
Lou, who helped take Cingulate public in 2021 on
Nasdaq, expressed gratitude to the Kansas City Business Journal,
adding that he and the Cingulate team are excited about the
economic future of the region.
“I am deeply humbled by this great honor,” Lou
commented. “Kansas City is such a special place to live and work,
and while the past two years have presented unique challenges and
difficult economic circumstances to businesses and CFOs nationwide,
Cingulate could not be more excited about the future or more proud
to call Kansas City home. This community remains one of the best
places in the entire Midwest to do business.”
About Louis G. Van HornLou is a
strategic finance leader with over 35 years of experience serving
in executive leadership roles across various industries including
pharmaceutical companies as well as global accounting firms.
Prior to joining Cingulate, Lou was Executive
Vice President and CFO at Store Financial Services, LLC. During his
tenure he led the finance organization, while also, at points,
serving as Chief Operating Officer and on the board of directors.
Prior to this, Lou was Vice President & Comptroller for Kansas
City Southern, a NYSE company, for 16 years. Earlier in his career,
he held finance and accounting roles at Shell Oil Company, Yellow
Freight Systems and PricewaterhouseCoopers. Lou has extensive
corporate and not-for-profit board experience and was also
recognized by the Kansas City Business Journal as CFO of the Year
in 2012. About Cingulate® Cingulate
Inc. (NASDAQ: CING), is a clinical-stage biopharmaceutical company
utilizing its proprietary PTR™ drug delivery platform technology to
build and advance a pipeline of next-generation pharmaceutical
products, designed to improve the lives of patients suffering from
frequently diagnosed conditions characterized by burdensome daily
dosing regimens and suboptimal treatment outcomes. With an initial
focus on the treatment of ADHD, Cingulate is identifying and
evaluating additional therapeutic areas where PTR™ technology may
be employed to develop future product candidates, including to
treat anxiety disorders.
Cingulate is headquartered in Kansas City.
For more information
visit Cingulate.com
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements include all statements, other than statements of
historical fact, regarding our current views and assumptions with
respect to future events regarding our business, including
statements with respect to our plans, assumptions, expectations,
beliefs and objectives with respect to product development,
clinical studies, clinical and regulatory timelines, market
opportunity, competitive position, business strategies, potential
growth opportunities and other statements that are predictive in
nature.
These statements are generally identified by the
use of such words as “may,” “could,” “should,” “would,” “believe,”
“anticipate,” “forecast,” “estimate,” “expect,” “intend,” “plan,”
“continue,” “outlook,” “will,” “potential” and similar statements
of a future or forward-looking nature. Readers are cautioned that
any forward-looking information provided by us or on our behalf is
not a guarantee of future performance. Actual results may differ
materially from those contained in these forward-looking statements
as a result of various factors disclosed in our filings with the
Securities and Exchange Commission (SEC), including the “Risk
Factors” section of our Annual Report on Form 10-K filed with the
SEC on March 28, 2022. All forward-looking statements speak only as
of the date on which they are made, and we undertake no duty to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except to
the extent required by law.
Contacts: |
|
Investor
Relations Thomas Dalton Head of Investor & Public
Relations, CingulateTDalton@cingulate.com913-942-2301 |
Media RelationsMelyssa WeibleElixir Health Public
Relationsmweible@elixirhealthpr.com201-723-5805 |
Matt Kreps Darrow Associates
mkreps@darrowir.com 214-597-8200 |
|
Cingulate (NASDAQ:CING)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cingulate (NASDAQ:CING)
Historical Stock Chart
From Jul 2023 to Jul 2024